NKGen Biotech Activates New Clinical Trial Sites in Canada and Florida for Alzheimer’s Disease Treatment Study

NKGen Biotech (OTC: NKGN) has activated two new clinical trial sites, Ottawa Memory Clinic (Canada) and AdventHealth Orlando (Florida), for its Phase 1/2a trial of troculeucel, an autologous NK cell therapy for moderate Alzheimer's disease. This expansion enhances patient recruitment capabilities and broadens trial diversity, following Health Canada clearance for Canadian participation. Despite over $5 million in recent insider stock purchases, the company saw significant institutional investor outflows in Q1 2025, with 27 funds decreasing positions, including several major funds divesting 100% of their holdings, highlighting a divergence in investor activity amidst clinical progress.

Analysis

NKGen Biotech (NKGN) is demonstrating operational progress in its clinical pipeline by activating two new trial sites for its Phase 1/2a study of troculeucel, a novel cell therapy for moderate Alzheimer's disease. This expansion into Canada and Florida, supported by clearance from Health Canada and the involvement of respected researchers, is a critical step to accelerate patient enrollment and enhance an otherwise high-risk, early-stage trial. However, this positive operational development is occurring against a backdrop of sharply diverging investor sentiment. While company insiders, including the CEO, have demonstrated significant conviction through the purchase of over $5.1 million in stock with no sales in the last six months, institutional investors have moved in the opposite direction. Data from the most recent quarter shows a substantial exodus, with 27 funds decreasing their positions and several liquidating their holdings entirely. This divergence suggests that while management is bullish on the long-term clinical potential, institutional capital may be wary of the inherent risks, potential need for future financing as noted in the company's forward-looking statements, and the long, uncertain timeline associated with Alzheimer's drug development.

Key Decisions for Investors

• Investors should weigh the strong bullish signal from recent multi-million dollar insider purchases against the significant bearish signal of widespread institutional divestment in the last quarter.
• Given the company's clinical-stage status, portfolio allocation should reflect the high-risk, high-reward nature of the investment, with a focus on upcoming clinical trial catalysts like enrollment updates and interim data from the Phase 1/2a study.
• Monitor the company's capital position closely, as the forward-looking statements highlight a need for additional funding, which could lead to dilutive financing events and may be a key factor driving institutional exits.